Miami Membrane for Potency (MMEP) Trial
NCT02710422 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24
Last updated 2019-09-11
Summary
The use of dehydrated human amnionic membrane allograft improves erectile function recovery (as measured by (Sexual History Inventory for Men (SHIM) score) at 12 months after robotic assisted radical prostatectomy (RARP) compared to a control group with no allograft.
Conditions
Interventions
- BIOLOGICAL
-
Amniotic Membrane Placement
Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
- BEHAVIORAL
-
EPIC 26
Participants will receive EPIC 26 psychosocial questionnaire at baseline, and post-RARP at protocol-defined intervals.
- OTHER
-
PSA Measurement
Measurement of serum PSA levels every three months (+ 1 month) for first year post surgery, and then annually for 5 years.
- BEHAVIORAL
-
Sexual History Inventory for Men
SHIM psychosocial questionnaire administered at baseline, and post-RARP at protocol-defined intervals.
Sponsors & Collaborators
-
Vivex Biomedical
collaborator UNKNOWN -
University of Miami
lead OTHER
Principal Investigators
-
Sanoj Punnen, MD · University of Miami
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- PARALLEL
Eligibility
- Min Age
- 40 Years
- Max Age
- 80 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-05-17
- Primary Completion
- 2019-01-22
- Completion
- 2019-01-22
- FDA Drug
- Yes
Countries
- United States
Study Locations
More Related Trials
-
An Open-label Extension Study of PSMA ADC 2301 in mCRPC
NCT02020135 ·Status: COMPLETED ·Phase: PHASE2
-
Neoadjuvant High Dose Rate Brachytherapy Prior to Radical Prostatectomy in Patients With Prostate Cancer
NCT07182279 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Detection of ARv7 in the Plasma of Men With Advanced Metastatic Castrate Resistant Prostate Cancer (MCRP)
NCT03236688 ·Status: SUSPENDED
-
177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT07219147 ·Status: RECRUITING ·Phase: PHASE1
-
Prophylactic Urethral Stenting With Memokath After Prostate Implantation for Prostate Adenocarcinoma
NCT00252941 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Memantine Hydrochloride in Prostate Cancer Patients
NCT07164794 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
NCT03436654 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation
NCT04104893 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
COMbination of Bipolar Androgen Therapy and Nivolumab
NCT03554317 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Cancer-Related Bone Pain by Using Bone-Targeted Radiation-Based Therapy (Sn-117m-DTPA) in Patients With Prostate Cancer That Has Spread to Bones
NCT04616547 ·Status: TERMINATED ·Phase: PHASE2
-
Phase II Trial to Investigate the Safety and Efficacy of Four Dosing Regimens of OTL78 Injection
NCT06849544 ·Status: RECRUITING ·Phase: PHASE2
-
Treatment Outcomes in a Non-study Population of Symptomatic mCRPC Patients Treated With Radium-223
NCT03223727 ·Status: COMPLETED
-
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
NCT05551117 ·Status: TERMINATED ·Phase: PHASE2
-
Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)
NCT01140373 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
AMG 208 Tumor Microenvironment in Metastatic Castration Resistant Prostate Cancer (mCRPC)
NCT02420587 ·Status: WITHDRAWN ·Phase: PHASE2
-
Androgen Deprivation, With or Without pTVG-AR, and With or Without T-Cell Checkpoint Blockade, in Patients With Newly Diagnosed, High-Risk Prostate Cancer
NCT04989946 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
GZ17-6.02 in Advanced CRPC After Progression on Anti-Androgen Therapy
NCT06636123 ·Status: RECRUITING ·Phase: PHASE1
-
Multi-Center Phase II Study to Compare MER-101 20mg Tablets to Intravenous Zometa 4mg in Male Bisphosphonate-Naive, Hormone Refractory Prostate Cancer Patients
NCT00636740 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT06377683 ·Status: COMPLETED ·Phase: PHASE1
-
An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
NCT05939414 ·Status: RECRUITING ·Phase: PHASE3
-
Phase I Study of 225Ac-J591 Plus 177Lu-PSMA Small Molecule for Progressive Metastatic Castration Resistant Prostate Cancer
NCT04886986 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
NCT04126070 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Personalized Mini-PDX for Metastatic CRPC
NCT03786848 ·Status: UNKNOWN ·Phase: NA
-
Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone
NCT02023697 ·Status: COMPLETED ·Phase: PHASE2
-
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer
NCT00589472 ·Status: COMPLETED ·Phase: PHASE2